Back to today’s briefing

Story perspectives

China Boosts AI Drug Development with METiS TechBio Investment

2/11/2026

26 6 Full Breakdown

Summary

Story summary

China is increasing investment in AI-driven drug developers to boost self-reliance.
METiS TechBio, based in Hangzhou, raised 400 million yuan in Series D financing in 2025, led by government-linked funds.
The company has developed MTS-004, an oral treatment for neurological disorders, and completed Phase III trials.
METiS plans to seek regulatory approval in China this year and may pursue a Hong Kong IPO raising about US$200 million.

1 of 1

Story summary

China is increasing investment in AI-driven drug developers to boost self-reliance.
METiS TechBio, based in Hangzhou, raised 400 million yuan in Series D financing in 2025, led by government-linked funds.
The company has developed MTS-004, an oral treatment for neurological disorders, and completed Phase III trials.
METiS plans to seek regulatory approval in China this year and may pursue a Hong Kong IPO raising about US$200 million.